The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
April 17th 2024
Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Dr Robert Gabbay Discusses SGLT2 Inhibitor Uptake Among Cardiologists, Nephrologists
October 29th 2021As time goes on, we're finding out more and more benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association.
Watch
Hypoglycemia Upon Hospital Admission From Long-term Care: Health Care Resource Use
This analysis of a hospital billing database describes inpatient length of stay, intensive care unit length of stay, comorbidities, and costs for patients with diabetes after admission with hypoglycemia from long-term care or home.
Read More
Patient and Supporter Factors Affecting Engagement With Diabetes Telehealth
Family support with medication management and recent urgent self-management concerns are 2 novel factors, among others, that predict completion of diabetes telehealth calls.
Read More
Results of a representative study of patients at federally qualified health centers found Medicaid expansion was associated with reduced rates of uninsurance, improved blood pressure and diabetes control measures, and progress in closing racial care disparities over 5 years.
Read More
Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says
September 20th 2021New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.
Read More
FDA Grants Empagliflozin Breakthrough Therapy Designation in HFpEF
September 9th 2021The sodium glucose co-transporter 2 (SGLT2) inhibitor reduced cardiovascular death and hospitalization for heart failure by 21% in results presented August 27 during the recent European Society of Cardiology Congress.
Read More
Dr Deepak L. Bhatt Discusses SGLT Inhibitors’ Impact on Glycemic Control
August 30th 2021Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, outlines the role that sodium glucose co-transporter (SGLT) inhibitors play in patients with diabetes and diminished glomerular filtration rates.
Watch
Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes
Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.
Read More